STTK DR3 blockade touts durable efficacy; Crohn’s data slated for 2028
STTK’s DR3 blockade for IBD is presented as having advantages in immunogenicity and target stability over TL1A, with SL-325 showing durable receptor occupancy and low ADA rates. Phase II Crohn’s data is expected in 2028.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.